Muken Ross 4/A

What Happened

• Muken Ross, President of SOPHiA GENETICS SA (SOPH), was granted equity awards on April 2, 2026: 431,211 restricted stock units (RSUs) and 628,743 derivative awards (a share option/derivative). Both items were reported as acquisitions at a $0.00 price (typical for grants), for a combined grant amount of 1,059,954 shares. The filing is an amendment to the Form 4 originally filed April 3, 2026 to correct the ownership total.

Key Details

• Transaction date: 2026-04-02; reported in original Form 4 on 2026-04-03 and amended on 2026-04-08 to correct reported ownership.
• Grants reported: 431,211 RSUs (A) and 628,743 derivative awards/options (A); price reported $0.00 for both.
• Shares beneficially owned following transaction: 703,121 ordinary shares (corrected amount per Form 4/A).
• Vesting: RSUs — 25% on April 2, 2027, then remaining 75% in equal quarterly installments through April 2, 2030 (F1). Share option — 25% on April 2, 2027, then equal monthly installments through April 2, 2030 (F3).
• Filing status: This is an amended filing (F2) that corrects the previously reported ownership number; there is no indication the original filing was materially late.

Context

• RSUs are contingent rights to receive shares upon vesting (not an immediate cash purchase); the derivative award is a share option that vests over time per the schedule above. Such grants are common as part of executive compensation and do not by themselves indicate the insider bought or sold shares on the open market.
• Retail investors should note the size and multi-year vesting schedule of these awards (aligns executive pay with long-term service/ performance) and that the beneficially owned total was corrected by amendment.